Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Orionis Biosciences

Private
#Induced Proximity Therapeutics#Molecular Glue Degraders#Oncology#Immunology#Protein Degradation

Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.

Company Info

Sector:Biotechnology / Induced Proximity Therapeutics
Headquarters:Waltham, Massachusetts, USA (Research facility in Ghent, Belgium)
Founded:2015
Website:www.orionisbio.com/
Funding Round:Series C and ongoing partnerships
Total Funding:~$200M (cumulative equity + upfront payments)

Funding & Investor Relations

Notable Investors

  • Novartis (collaboration partner)
  • Genentech / Roche (collaboration partner)
  • Atlas Venture
  • LSP (Life Sciences Partners)
  • Bristol-Myers Squibb
  • INKEF Capital
  • VIB (Flemish Institute for Biotechnology)

IPO Outlook / Plans

None publicly disclosed; private biotech with strong pharma partnership revenue.

Upcoming Milestones & Key Dates

2026
Milestone

Nomination of first development candidate from Novartis collaboration

2026 / 2027
Clinical Trial

Phase 1 clinical updates for ORB-011 and ORB-021 A-Kine programs

Clinical Development Pipeline

ORB-011

Target: Conditionally active cDC1-targeted interferon (A-Kine)
Advanced Solid Tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ORB-021

Target: Conditionally active targeted cytokine (A-Kine)
Advanced Solid Tumors
Preclinical
Phase 1
Phase 2
Phase 3
Approved

AlloGlue programs (with Novartis)

Target: Multiple molecular glue degraders via induced proximity
Multiple undisclosed oncology and immunology targets
Preclinical
Phase 1
Phase 2
Phase 3
Approved

AlloGlue programs (with Genentech/Roche)

Target: Multiple molecular glue degraders via induced proximity
Multiple undisclosed targets
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Dr. Niko Kley

Co-Founder and Chief Executive Officer

Dr. Stefano Crosignani

Vice President, Research and Scientific Operations

Dr. Stefan Bekiranov

Vice President, Computational Biology and AI

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →